United States securities and exchange commission logo





                           April 27, 2023

       Rudy C. Howard
       Chief Financial Officer
       Aravive, Inc.
       River Oaks Tower
       3730 Kirby Drive, Suite 1200
       Houston , Texas 77098

                                                        Re: Aravive, Inc.
                                                            Form 10-K for
Fiscal Year Ended December 31, 2022
                                                            Filed March 15,
2023
                                                            File No. 001-36361

       Dear Rudy C. Howard:

              We have limited our review of your filing to the financial
statements and related
       disclosures and have the following comments. In some of our comments, we
may ask you to
       provide us with information so we may better understand your disclosure.

              Please respond to these comments within ten business days by
providing the requested
       information or advise us as soon as possible when you will respond. If
you do not believe our
       comments apply to your facts and circumstances, please tell us why in
your response.

                                                        After reviewing your
response to these comments, we may have additional comments.

       Form 10-K for Fiscal Year Ended December 31, 2022

       Management's Discussion and Analysis of Financial Condition and Results
of Operations
       Results of Operations
       Research and Development expense, page 61

   1.                                                   Please revise the
Result of Operations section in your future filings to provide
                                                        a breakdown of your
research and development expense by product candidate. For any
                                                        amounts that you do not
allocate by product candidate, provide a breakdown by nature of
                                                        expenses. Provide us
with a copy of your proposed disclosure in your response letter.
 Rudy C. Howard
Aravive, Inc.
April 27, 2023
Page 2
Consolidated Financial Statements
Notes to Consolidated Financial Statements
5. Collaboration and License Agreement , page F-17

2.       With regards to your collaboration and license agreement with 3D
Medicines, please tell
         us how you concluded that the license was distinct and had standalone
value under ASC
         606-10-25-19 through 25- 22, specifically addressing ASC
606-10-25-19(b.) In this
         regard, explain why your license was considered to have the ability to
treat a condition,
         with no expectation that the company will undertake activities to
change the functionality
         of the drug formula during the license period. In your response,
please specifically address
         the considerations given to your obligation to continue to transfer
Aravive Licensed
         Know-How as required for the filing of an MAA in the 3D Medicines
Territory and any
         other Aravive Licensed Know-How that subsequently comes into existence
and
         becomes Controlled by Aravive or its Affiliates during the Term, as
defined under Section
         2.6 of your license agreement. Refer to ASC 606-10-55-364 through
55-374, Example 55
         and 56.
       In closing, we remind you that the company and its management are
responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review,
comments, action or
absence of action by the staff.

       You may contact Ibolya Ignat at 202-551-3636 or Li Xiao at 202-551-4391
with any
questions.



FirstName LastNameRudy C. Howard                               Sincerely,
Comapany NameAravive, Inc.
                                                               Division of
Corporation Finance
April 27, 2023 Page 2                                          Office of Life
Sciences
FirstName LastName